Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Will Blincyto's Expanded FDA Approval Open the Door for Wider Use of MRD as a Biomarker or Endpoint?
Will Blincyto's Expanded FDA Approval Open the Door for Wider Use of MRD as a Biomarker or Endpoint?
Will Blincyto's Expanded FDA Approval Open the Door for Wider Use of MRD as a Biomarker or Endpoint?
Submitted by
admin
on April 3, 2018 - 11:04pm
Source:
RAPS.org
News Tags:
Amgen
Blincyto
ALL
B-cell precursor ALL
Headline:
Will Blincyto's Expanded FDA Approval Open the Door for Wider Use of MRD as a Biomarker or Endpoint?
Do Not Allow Advertisers to Use My Personal information
